CSCIF
COSCIENS Biopharma Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Apr 20 COSCIENS Biopharma is proposing a share capital amendment involving…
- R May 12 COSCIENS Biopharma reported Q1 2026 results showing a net loss from…
- R Jul 6 COSCIENS Biopharma completed a 1:150 reverse stock split followed by…
- X Aug 14 Short interest jumps 57.7% to 1.6K
- X Aug 31 Short interest falls 28.1% to 1.1K
- X Sep 30 Short interest jumps 50.2% to 1.7K
- X Oct 15 Short interest jumps 134.5% to 4.0K
Signal stack
Where each data set points today.
- Short sellersBUILDING
Short interest +134.5% to 4.0K shares. 3.4 days to cover.
- TrendUPTREND
5% above its 50-day average.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
6 filings · 0 bullish · 1 bearish · 2 mixed · 3 neutral- BEARISH 6-KJul 6, 2026
COSCIENS Biopharma completed a 1:150 reverse stock split followed by a 50:1 forward split (net 1:3…
The impending SEC deregistration is a clear negative for U.S. OTC holders, likely reducing liquidity and potentially leading to delisting from OTCQB. Traders should monitor the OTCQB eligibility…
- NEUTRAL 6-KJun 18, 2026
COSCIENS Biopharma Inc. reported results from its annual general and special meeting held June 17…
Monitor for further details on the implementation timeline of the share capital amendment, which will affect share count and trading mechanics. The CEO appointment signals leadership continuity but…
- MIXED 6-KMay 12, 2026
COSCIENS Biopharma reported Q1 2026 results showing a net loss from continuing operations of $0.2…
The deconsolidation of German subsidiaries is a one-time accounting gain that masks a still-struggling active ingredients business. Monitor the June 17 shareholder vote on the share reorganization…
- NEUTRAL 6-KMay 8, 2026
COSCIENS Biopharma filed a 6-K announcing its Annual General and Special Meeting of shareholders…
Monitor the meeting outcomes (e.g., director elections, shareholder proposals) which could provide signals on governance or strategy, but this filing alone has no trading implications.
All CSCIF filing & press-release reports (6)
- 6-K reportJul 6, 2026
- 6-K reportJun 18, 2026
- 6-K reportMay 12, 2026
- 6-K reportMay 8, 2026
- 6-K reportApr 20, 2026
- EFFECT reportMar 19, 2026